YCBD vs. ESPR
YCBD (cbdMD, Inc.) and ESPR (Esperion Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — YCBD in Drug Manufacturers - Specialty & Generic, ESPR in Biotechnology. Over the past 5 years, YCBD returned -77.03%/yr vs -31.52%/yr for ESPR. At a 0.07 correlation, their price movements are largely independent.
Performance
YCBD vs. ESPR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, YCBD achieves a -48.14% return, which is significantly lower than ESPR's -15.14% return.
YCBD
- 1D
- -6.65%
- 1M
- -18.20%
- YTD
- -48.14%
- 6M
- 18.14%
- 1Y
- -28.52%
- 3Y*
- -64.40%
- 5Y*
- -77.03%
- 10Y*
- —
ESPR
- 1D
- 0.00%
- 1M
- 0.64%
- YTD
- -15.14%
- 6M
- -16.93%
- 1Y
- 199.05%
- 3Y*
- 32.17%
- 5Y*
- -31.52%
- 10Y*
- -15.52%
YCBD vs. ESPR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
YCBD cbdMD, Inc. | -48.14% | -55.00% | -63.94% | -89.82% | -78.98% | -63.39% | 30.53% | -59.28% |
ESPR Esperion Therapeutics, Inc. | -15.14% | 68.18% | -26.42% | -52.01% | 24.60% | -80.77% | -56.40% | 38.00% |
Correlation
The correlation between YCBD and ESPR is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.06 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since Apr 30, 2019 | 0.07 |
Fundamentals
YCBD:
$7.31M
ESPR:
$789.25M
YCBD:
-$102.92
ESPR:
-$0.03
YCBD:
0.00
ESPR:
1.75
YCBD:
$5.65B
ESPR:
$418.24M
YCBD:
$3.26B
ESPR:
$226.32M
YCBD:
-$801.36M
ESPR:
$77.18M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
YCBD vs. ESPR — Risk / Return Rank
YCBD
ESPR
YCBD vs. ESPR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for cbdMD, Inc. (YCBD) and Esperion Therapeutics, Inc. (ESPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| YCBD | ESPR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.30 | ||
| Sortino ratioReturn per unit of downside risk | -1.76 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.39 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.40 | 3.77 | -4.17 |
| Martin ratioReturn relative to average drawdown | -0.60 | 9.52 | -10.12 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| YCBD | ESPR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.15 | 2.15 | -2.30 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.59 | -0.34 | -0.24 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.54 | -0.13 | -0.40 |
Drawdowns
YCBD vs. ESPR - Drawdown Comparison
The maximum YCBD drawdown since its inception was -99.98%, roughly equal to the maximum ESPR drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for YCBD and ESPR.
Loading charts...
Drawdown Indicators
| YCBD | ESPR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -99.37% | -0.61% |
Max Drawdown (1Y)Largest decline over 1 year | -71.19% | -53.19% | -18.00% |
Max Drawdown (3Y)Largest decline over 3 years | -96.91% | -80.94% | -15.97% |
Max Drawdown (5Y)Largest decline over 5 years | -99.96% | -97.23% | -2.73% |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.10% | — |
Current DrawdownCurrent decline from peak | -99.97% | -97.28% | -2.69% |
Average DrawdownAverage peak-to-trough decline | -82.45% | -69.92% | -12.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.52% | 21.00% | +26.52% |
Volatility
YCBD vs. ESPR - Volatility Comparison
cbdMD, Inc. (YCBD) has a higher volatility of 17.88% compared to Esperion Therapeutics, Inc. (ESPR) at 1.30%. This indicates that YCBD's price experiences larger fluctuations and is considered to be riskier than ESPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| YCBD | ESPR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.88% | 1.30% | +16.58% |
Volatility (6M)Calculated over the trailing 6-month period | 116.48% | 61.84% | +54.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 194.31% | 94.06% | +100.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 131.57% | 91.97% | +39.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 125.73% | 84.71% | +41.02% |
Dividends
YCBD vs. ESPR - Dividend Comparison
Neither YCBD nor ESPR has paid dividends to shareholders.
Financials
YCBD vs. ESPR - Financials Comparison
This section allows you to compare key financial metrics between cbdMD, Inc. and Esperion Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
YCBD vs. ESPR - Profitability Comparison
YCBD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, cbdMD, Inc. reported a gross profit of 3.26B and revenue of 5.64B. Therefore, the gross margin over that period was 57.8%.
ESPR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.
YCBD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, cbdMD, Inc. reported an operating income of -800.78M and revenue of 5.64B, resulting in an operating margin of -14.2%.
ESPR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.
YCBD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, cbdMD, Inc. reported a net income of -876.78M and revenue of 5.64B, resulting in a net margin of -15.6%.
ESPR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.
Frequently Asked Questions
YCBD and ESPR have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
YCBD has higher volatility (17.88%) compared to ESPR (1.30%). In terms of maximum drawdown, YCBD dropped -99.98% vs ESPR's -99.37%.
ESPR currently has the higher Sharpe Ratio (2.15 vs -0.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for YCBD and ESPR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer